Importance of risk assessment in timing of invasive coronary evaluation and treatment of patients with non–st-segment– elevation acute coronary syndrome: Insights from the verdict trial
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 848 KB, PDF document
BACKGROUND: The optimal timing of invasive examination and treatment of high-risk patients with non–ST-segment–elevation acute coronary syndrome has not been established. We investigated the efficacy of early invasive coronary angiography compared with standard-care invasive coronary angiography on the risk of all-cause mortality according to the GRACE (Global Registry of Acute Coronary Events) risk score in a predefined subgroup analysis of the VERDICT (Very Early Versus Deferred Invasive Evaluation Using Computerized Tomography) trial. METHODS AND RESULTS: Patients with clinical suspicion of non–ST-segment–elevation acute coronary syndrome with ECG changes indicating new ischemia and/or elevated troponin, in whom invasive coronary angiography was clinically indicated and deemed logistically feasible within 12 hours, were eligible for inclusion. Patients were randomized 1:1 to an early (≤12 hours) or standard (48–72 hours) invasive strategy. The primary outcome of the present study was all-cause mortality. Of 2147 patients randomized in the VERDICT trial, 2092 patients had an available GRACE risk score. Of these, 1021 (48.8%) patients had a GRACE score >140. During a median follow-up of 4.1 years, 192 (18.8%) and 54 (5.0%) patients died in the high and low GRACE score groups, respectively. The risk of death with the early invasive strategy was increased in patients with a GRACE score ≤140 (hazard ratio [HR], 2.04 [95% CI, 1.16–3.59]), whereas there was a trend toward a decreased risk of death with the early invasive strategy in patients with a GRACE score >140 (HR, 0.83 [95% CI, 0.63–1.10]) (Pinteraction =0.006). CONCLUSIONS: In patients with non–ST-segment–elevation acute coronary syndrome, we found a significant interaction between timing of invasive coronary angiography and GRACE score on the risk of death. Randomized clinical trials are warranted to establish the efficacy and safety among high-risk and low-risk patients with non–ST-segment–elevation acute coronary syndrome. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02061891.
Original language | English |
---|---|
Article number | e022333 |
Journal | Journal of the American Heart Association |
Volume | 10 |
Issue number | 19 |
Number of pages | 16 |
ISSN | 2047-9980 |
DOIs | |
Publication status | Published - 2021 |
Bibliographical note
Publisher Copyright:
© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
- Acute coronary syndrome, GRACE score, Heart failure, Invasive coronary angiography, Mortality
Research areas
ID: 301819945